These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 19182452)
1. [Pharmacogenomics: inter-ethnic and intra-ethnic differences in pharmacokinetic and pharmacodynamic profiles of clinically relevant drugs]. Ieiri I; Higuchi S Yakugaku Zasshi; 2009 Feb; 129(2):231-5. PubMed ID: 19182452 [TBL] [Abstract][Full Text] [Related]
2. The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy. Romaine SP; Bailey KM; Hall AS; Balmforth AJ Pharmacogenomics J; 2010 Feb; 10(1):1-11. PubMed ID: 19884908 [TBL] [Abstract][Full Text] [Related]
3. The role of OATP1B1 and BCRP in pharmacokinetics and DDI of novel statins. Hua WJ; Hua WX; Fang HJ Cardiovasc Ther; 2012 Oct; 30(5):e234-41. PubMed ID: 21884024 [TBL] [Abstract][Full Text] [Related]
4. The effect of herbal medicine baicalin on pharmacokinetics of rosuvastatin, substrate of organic anion-transporting polypeptide 1B1. Fan L; Zhang W; Guo D; Tan ZR; Xu P; Li Q; Liu YZ; Zhang L; He TY; Hu DL; Wang D; Zhou HH Clin Pharmacol Ther; 2008 Mar; 83(3):471-6. PubMed ID: 17851565 [TBL] [Abstract][Full Text] [Related]
5. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Lee E; Ryan S; Birmingham B; Zalikowski J; March R; Ambrose H; Moore R; Lee C; Chen Y; Schneck D Clin Pharmacol Ther; 2005 Oct; 78(4):330-41. PubMed ID: 16198652 [TBL] [Abstract][Full Text] [Related]
6. Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans. Choi JH; Lee MG; Cho JY; Lee JE; Kim KH; Park K Clin Pharmacol Ther; 2008 Feb; 83(2):251-7. PubMed ID: 17568401 [TBL] [Abstract][Full Text] [Related]
7. Ethnic variability in the plasma exposures of OATP1B1 substrates such as HMG-CoA reductase inhibitors: a kinetic consideration of its mechanism. Tomita Y; Maeda K; Sugiyama Y Clin Pharmacol Ther; 2013 Jul; 94(1):37-51. PubMed ID: 23443754 [TBL] [Abstract][Full Text] [Related]
9. [Effect of OATP1B1 521T --> C heterogenesis on pharmacokinetic characterstics of rosuvastatin in Chinese volunteers]. Sui SM; Wen JH; Li XH; Xiong YQ Yao Xue Xue Bao; 2011 Jun; 46(6):695-700. PubMed ID: 21882531 [TBL] [Abstract][Full Text] [Related]
10. Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs. Ieiri I; Higuchi S; Sugiyama Y Expert Opin Drug Metab Toxicol; 2009 Jul; 5(7):703-29. PubMed ID: 19442037 [TBL] [Abstract][Full Text] [Related]
11. Interaction of novel platelet-increasing agent eltrombopag with rosuvastatin via breast cancer resistance protein in humans. Takeuchi K; Sugiura T; Matsubara K; Sato R; Shimizu T; Masuo Y; Horikawa M; Nakamichi N; Ishiwata N; Kato Y Drug Metab Dispos; 2014 Apr; 42(4):726-34. PubMed ID: 24440960 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor. Kulmatycki K; Hanna I; Meyers D; Salunke A; Movva A; Majumdar T; Natrillo A; Vapurcuyan A; Rebello S; Sunkara G; Chen J Int J Clin Pharmacol Ther; 2015 May; 53(5):345-55. PubMed ID: 25740267 [TBL] [Abstract][Full Text] [Related]
13. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. Maeda K; Ieiri I; Yasuda K; Fujino A; Fujiwara H; Otsubo K; Hirano M; Watanabe T; Kitamura Y; Kusuhara H; Sugiyama Y Clin Pharmacol Ther; 2006 May; 79(5):427-39. PubMed ID: 16678545 [TBL] [Abstract][Full Text] [Related]
14. Drug-drug interactions between rosuvastatin and oral antidiabetic drugs occurring at the level of OATP1B1. van de Steeg E; Greupink R; Schreurs M; Nooijen IH; Verhoeckx KC; Hanemaaijer R; Ripken D; Monshouwer M; Vlaming ML; DeGroot J; Verwei M; Russel FG; Huisman MT; Wortelboer HM Drug Metab Dispos; 2013 Mar; 41(3):592-601. PubMed ID: 23248200 [TBL] [Abstract][Full Text] [Related]
15. Prediction of drug-drug interaction potential mediated by transporters between dasatinib and metformin, pravastatin, and rosuvastatin using physiologically based pharmacokinetic modeling. Chang M; Bathena S; Christopher LJ; Shen H; Roy A Cancer Chemother Pharmacol; 2022 Mar; 89(3):383-392. PubMed ID: 35147740 [TBL] [Abstract][Full Text] [Related]
16. Functional characterization of mouse organic anion transporting peptide 1a4 in the uptake and efflux of drugs across the blood-brain barrier. Ose A; Kusuhara H; Endo C; Tohyama K; Miyajima M; Kitamura S; Sugiyama Y Drug Metab Dispos; 2010 Jan; 38(1):168-76. PubMed ID: 19833843 [TBL] [Abstract][Full Text] [Related]
17. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Ho RH; Tirona RG; Leake BF; Glaeser H; Lee W; Lemke CJ; Wang Y; Kim RB Gastroenterology; 2006 May; 130(6):1793-806. PubMed ID: 16697742 [TBL] [Abstract][Full Text] [Related]
18. Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic and toxicological properties of anionic drugs. Maeda K; Sugiyama Y Drug Metab Pharmacokinet; 2008; 23(4):223-35. PubMed ID: 18762709 [TBL] [Abstract][Full Text] [Related]
19. Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans. Kivistö KT; Niemi M Pharm Res; 2007 Feb; 24(2):239-47. PubMed ID: 17177112 [TBL] [Abstract][Full Text] [Related]
20. Emerging Clinical Importance of Hepatic Organic Cation Transporter 1 (OCT1) in Drug Pharmacokinetics, Dynamics, Pharmacogenetic Variability, and Drug Interactions. Zamek-Gliszczynski MJ; Giacomini KM; Zhang L Clin Pharmacol Ther; 2018 May; 103(5):758-760. PubMed ID: 29193038 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]